Ospemifene: Phase III started

Shionogi began a double-blind, placebo-controlled, U.S. Phase III trial to evaluate 60 mg oral Osphena once daily in about 600 patients. Osphena is approved in the U.S. to treat dyspareunia due to menopause. ...